Integrin antagonists are effective and safe for Crohn’s disease: A meta-analysis

Figure 1 Flow diagram of the studies identified.

Figure 2 Forest plots of clinical response. Clinical response was defined as a decrement of ≥ 70 points in CDAI score from baseline (week 0). Ghosh 2003¹: 6 mg/kg natalizumab at 0 and 4 wk; Ghosh 2003²: 3 mg/kg natalizumab at 0 and 4 wk; Ghosh 2003³: 3 mg/kg natalizumab at 0 wk. Feagan 2008¹: 2 mg/kg vedolizumab at 0 and 4 wk; Feagan 2008²: 0.5 mg/kg vedolizumab at 0 and 4 wk.

Figure 3 Forest plots of clinical remission. Clinical remission was defined as CDAI score < 150. Ghosh 2003¹: 6 mg/kg natalizumab at 0 and 4 wk; Ghosh 2003²: 3 mg/kg natalizumab at 0 and 4 wk; Ghosh 2003³: 3 mg/kg natalizumab at 0 wk. Feagan 2008¹: 2 mg/kg vedolizumab at 0 and 4 wk; Feagan 2008²: 0.5 mg/kg vedolizumab at 0 and 4 wk.

Figure 4 Forest plots of common adverse reactions. Ghosh 2003¹: 6 mg/kg natalizumab at 0 and 4 wk; Ghosh 2003²: 3 mg/kg natalizumab at 0 and 4 wk; Ghosh 2003³: 3 mg/kg natalizumab at 0 wk. Feagan 2008¹: 2 mg/kg vedolizumab at 0 and 4 wk; Feagan 2008²: 0.5 mg/kg vedolizumab at 0 and 4 wk.

Figure 5 Forest plots of serious adverse reactions. Ghosh 2003¹: 6 mg/kg natalizumab at 0 and 4 wk; Ghosh 2003²: 3 mg/kg natalizumab at 0 and 4 wk; Ghosh 2003³: 3 mg/kg natalizumab at 0 wk. Feagan 2008¹: 2 mg/kg vedolizumab at 0 and 4 wk; Feagan 2008²: 0.5 mg/kg vedolizumab at 0 and 4 wk.